Sickle cell disease trials recruiting in New York

All Sickle cell disease trials nationally

Cities in New York

Recruiting trials in New York

• 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
  NCT07015684 · Phase: Phase 1 · Ages: 12 Years to 50 Years · Sex: All (male and female) · New York: New York
• A Long-term Follow-up Study in Patients Who Received BEAM-101
  NCT07373639 · Phase: Not specified · Ages: 14 Years to 37 Years · Sex: All (male and female) · New York: New York
• A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
  NCT07187973 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
  NCT05431088 · Phase: Phase 2, Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · New York: New York, The Bronx
• A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
  NCT06609226 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · New York: Brooklyn, New York, The Bronx
• A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
  NCT05736419 · Phase: Phase 2 · Ages: 2 Years to 50 Years · Sex: All (male and female) · New York: Commack, Harrison, Rockville Centre
• A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
  NCT06612268 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · New York: Brooklyn, Mount Kisco, Queens, The Bronx
• A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
  NCT06439082 · Phase: Phase 3 · Ages: 12 Years to 100 Years · Sex: All (male and female) · New York: The Bronx
• ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
  NCT04398628 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · New York: Buffalo, Hyde Park, New York, Rochester
• AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
  NCT04099966 · Phase: Phase 2 · Ages: 1 Day to 30 Years · Sex: All (male and female) · New York: Valhalla
• Cannabidiol in Sickle Cell Disease
  NCT06930703 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Manhattan
• Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
  NCT05519111 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
  NCT06941389 · Phase: Not specified · Ages: 3 Years to 20 Years · Sex: All (male and female) · New York: Buffalo, New York, Queens, Rochester
• Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
  NCT05477563 · Phase: Phase 3 · Ages: 12 Years to 35 Years · Sex: All (male and female) · New York: New York
• Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
  NCT04819841 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 50 Years · Sex: All (male and female) · New York: New York
• Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
  NCT03587272 · Phase: Phase 2 · Ages: 2 Years to 25 Years · Sex: All (male and female) · New York: New York
• Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
  NCT02675959 · Phase: Phase 2 · Ages: 6 Months to 21 Years · Sex: All (male and female) · New York: Valhalla
• Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
  NCT06374238 · Phase: Not applicable (e.g. observational or device study) · Ages: 16 Years to 30 Years · Sex: All (male and female) · New York: New York, Rochester
• Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
  NCT07224360 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: The Bronx
• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
  NCT06699849 · Phase: Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · New York: New York, The Bronx
• The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
  NCT06975865 · Phase: Phase 3 · Ages: 10 Years to 65 Years · Sex: All (male and female) · New York: Staten Island, The Bronx